According to the NCCN and ESMO clinical practice guidelines, OFS should be considered an adjunctive therapy in premenopausal women with HR+/HER2− breast cancer (Gradishar et al., 2024; Loibl et al., 2024). Here, HR is linked to breast carcinoma.